Christina A. Clarke
Cancer Prevention Institute of California
222 Papers
1.7K Citations
Christina A. Clarke is an academic researcher from Cancer Prevention Institute of California. The author has contributed to research in topics: Population & Cancer. The author has an hindex of 62, co-authored 214 publications. Previous affiliations of Christina A. Clarke include Prevention Institute & LSU Health Sciences Center New Orleans.
Chat about Author
Papers
Spectrum of cancer risk among US solid organ transplant recipients.
Eric A. Engels,Ruth M. Pfeiffer,Joseph F. Fraumeni,Bertram L. Kasiske,Ajay K. Israni,Jon J. Snyder,Robert A. Wolfe,Nathan P. Goodrich,A. Rana Bayakly,Christina A. Clarke,Glenn Copeland,Jack L. Finch,Mary Lou Fleissner,Marc T. Goodman,Amy R. Kahn,Lori Koch,Charles F. Lynch,Margaret M. Madeleine,Karen Pawlish,Chandrika Rao,Melanie Williams,David Castenson,Michael Curry,Ruth Parsons,Gregory Fant,Monica Lin +25 more
TL;DR: Standardized incidence ratios and excess absolute risks assessing relative and absolute cancer risk in transplant recipients compared with the general population to describe the overall pattern of cancer following solid organ transplantation are described.
US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status
Nadia Howlader,Sean F. Altekruse,Christopher I. Li,Vivien W. Chen,Christina A. Clarke,Lynn A. G. Ries,Kathleen A. Cronin +6 more
TL;DR: In the future, SEER data can be used to monitor clinical outcomes in women diagnosed with different molecular subtypes of breast cancer for a large portion of the US population.
Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)
Lindsay M. Morton,Jennifer Turner,James R. Cerhan,Martha S. Linet,Patrick A. Treseler,Christina A. Clarke,Andrew Jack,Wendy Cozen,Marc Maynadié,John J. Spinelli,Adele Seniori Costantini,Thomas Rüdiger,Aldo Scarpa,Tongzhang Zheng,Dennis D. Weisenburger +14 more
TL;DR: It is recommended that epidemiologic studies include analyses by lymphoma subtype to the most detailed extent allowable by sample size and standardization of groupings is essential for comparing subtype-specific reports in the literature.
405
Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project
Lindsay M. Morton,Susan L. Slager,James R. Cerhan,Sophia S. Wang,Claire M. Vajdic,Christine F. Skibola,Paige M. Bracci,Silvia de Sanjosé,Karin E. Smedby,Brian C.-H. Chiu,Yawei Zhang,Sam M. Mbulaiteye,Alain Monnereau,Jennifer Turner,Jacqueline Clavel,Hans-Olov Adami,Hans-Olov Adami,Ellen T. Chang,Ellen T. Chang,Bengt Glimelius,Bengt Glimelius,Henrik Hjalgrim,Mads Melbye,Paolo Crosignani,Simonetta Di Lollo,Lucia Miligi,Oriana Nanni,Valerio Ramazzotti,Stefania Rodella,Adele Seniori Costantini,Emanuele Stagnaro,Rosario Tumino,Carla Vindigni,Paolo Vineis,Nikolaus Becker,Yolanda Benavente,Paolo Boffetta,Paul Brennan,Pierluigi Cocco,Lenka Foretova,Marc Maynadié,Alexandra Nieters,Anthony Staines,Joanne S. Colt,Wendy Cozen,Scott Davis,Scott Davis,Anneclaire J. De Roos,Patricia Hartge,Nathaniel Rothman,Richard K. Severson,Elizabeth A. Holly,Timothy G. Call,Andrew L. Feldman,Thomas M. Habermann,Mark Liebow,Aaron Blair,Kenneth P. Cantor,Eleanor Kane,Tracy Lightfoot,Eve Roman,Alex Smith,Angela Brooks-Wilson,Angela Brooks-Wilson,Joseph M. Connors,Randy D. Gascoyne,John J. Spinelli,Bruce K. Armstrong,Anne Kricker,Theodore R. Holford,Qing Lan,Tongzhang Zheng,Laurent Orsi,Luigino Dal Maso,Silvia Franceschi,Carlo La Vecchia,Carlo La Vecchia,Eva Negri,Diego Serraino,Leslie Bernstein,Alexandra M. Levine,Jonathan W. Friedberg,Jennifer L. Kelly,Sonja I. Berndt,Brenda M. Birmann,Christina A. Clarke,Christopher R. Flowers,James M. Foran,Marshall E. Kadin,Marshall E. Kadin,Ora Paltiel,Dennis D. Weisenburger,Martha S. Linet,Joshua N. Sampson +93 more
TL;DR: Using a novel approach to investigate etiologic heterogeneity among NHL subtypes,risk factors that were common among subtypes as well as risk factors that appeared to be distinct among individual or a few subtypes are identified, suggesting both subtype-specific and shared underlying mechanisms.
338
Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer
TL;DR: For patients with breast cancer, adverse outcomes are associated with delaying initiation of adjuvant chemotherapy 91 or more days, and the determinants of delays in chemotherapy initiation appeared to be sociodemographic, and clinicians should provide timelier care to all patients.